Bioartemis GmbH
About
I advise US and European biotech companies on EU expansion, portfolio strategy, and late-stage execution, helping transform scientific assets into successful global therapies.
I work with CEOs, founders, and investors to de-risk key inflection points, from early portfolio decisions to Phase 2–3 transitions and European launch readiness.
Focus areas:
-
EU expansion strategy (turning Europe into a growth driver)
-
Building & scaling Medical Affairs from Phase 2 through launch
-
Portfolio & program strategy (early to late stage)
-
Phase 2 → launch readiness (evidence, KOLs, access)
-
Investor & board support (due diligence, positioning)
Experience: Pfizer, Celgene, Novartis, Biogen, Alnylam Pharmaceuticals, Mayne Pharma, Rejuveron, Oxthera, Nektar, Cyclarity, Nanotics
What is your business/industry sector?